Compare BioNTech SE - ADR (BNTX) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs General Motors Company — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while General Motors Company trades at $89.5 (market cap $78.40B). The key difference: General Motors Company is far larger — about 3.4× BioNTech SE - ADR's market cap, and General Motors Company pays a 0.81% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | GM | |
|---|---|---|
Market Cap | $23.31B | $78.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $90.30 |
52-Week Low | $83.89 | $54.16 |
Enterprise Value | $6.60B | $181.38B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
General Motors (GM) trades at $87.96, up 0.43% with a bullish technical signal and strong analyst support. The company shows robust cash flow generation ($26.87B operating cash flow in 2025) and has beaten earnings estimates for three consecutive quarters. Recent developments include a $4.5B parts supply deal and a renewed 20-year joint venture in China, positioning GM for supply chain stability and international growth.
GM presents a compelling investment case with 65% analyst buy ratings and a $108.82 consensus price target offering 24% upside. However, declining profit margins (1.05% net margin in 2025) and rising debt levels (46.79% debt-to-asset ratio) warrant caution. The stock's valuation appears reasonable with P/S of 0.45 and P/B of 1.26, but investors should monitor execution on EV strategy transitions and macroeconomic pressures on auto demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
